Back

The safety of in-hospital initiation of SGLT2 inhibitor with MRA therapy in patients hospitalized for heart failure with a reduced left ventricular ejection fraction and chronic kidney disease

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Understanding the effects and utilisation of SGLT2 inhibitors in heart failure Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mrs Oksana Obertynska

National Pirogov Memorial Medical University, Vinnitsa (Ukraine)

5 More presentations in this session

Presentation thumbnail
Effect of Dapagliflozin on health-related quality of life in patients with heart failure: a meta-analysis of Randomized Controlled Trials
Mrs M. De Souza (Curitiba, BR)
Abstract Slides Video
Presentation thumbnail
Disparities in SGLT2i utilization among heart failure patients with different ejection fraction in China: findings from chinese cardiovascular association database-heart failure center registry
Mr Q. Zhang (Beijing, CN)
Abstract Slides Video
Presentation thumbnail
Real-life data on the tolerability of SGLT2 inhibitors in elderly patients with heart failure
Mr A. Hacil (Paris, FR) Professor O. Hanon (Paris, FR)
Abstract Slides Video
Presentation thumbnail
Impact of dapagliflozin on supraventricular and ventricular arrhythmias, assessed by Holter ECG, in patients with heart failure with reduced ejection fraction
Professor A. ABDELLAH (Ismailia, EG)
Abstract Slides Video
Presentation thumbnail
Beneficial effects of the SGLT2 inhibition on oxidative skeletal muscle in infarcted rats
Miss L. Souza (Botucatu, BR)
Abstract Slides Video

Access the full session

Session thumbnail
Understanding the effects and utilisation of SGLT2 inhibitors in heart failure

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Addition of sodium-glucose cotransporter-2 inhibitors on steroidal mineralocorticoid receptor antagonists eliminates hyperkalemia risk in diabetic heart failure patients with chronic kidney disease
thumbnail
Congress Presentation
Low levels of irisin predicted worsening kidney function in dapagliflozin-treated patients with chronic heart failure and concomitant type 2 diabetes mellitus
thumbnail
Congress Presentation
Temporal trends in guideline-directed medical therapy prescription and 30-day readmission after heart failure hospitalization

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources